Cantor Fitzgerald Estimates Humacyte FY2025 Earnings

Humacyte, Inc. (NASDAQ:HUMA) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Humacyte in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the company will earn ($0.95) per share for the year. The consensus estimate for Humacyte’s current full-year earnings is ($1.27) per share.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.08). During the same period in the prior year, the firm earned ($0.25) EPS.

A number of other analysts have also weighed in on the company. TD Cowen restated a “buy” rating and set a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price (up previously from $12.00) on shares of Humacyte in a research note on Friday, December 20th. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the company a “neutral” rating in a research report on Friday, October 18th. BTIG Research reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. Finally, D. Boral Capital reissued a “buy” rating and set a $25.00 target price on shares of Humacyte in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Humacyte has an average rating of “Buy” and a consensus target price of $13.71.

Humacyte Stock Performance

Shares of HUMA opened at $4.61 on Thursday. The stock has a market capitalization of $580.21 million, a PE ratio of -3.44 and a beta of 1.32. The company has a 50 day moving average price of $4.52 and a 200-day moving average price of $5.63. Humacyte has a fifty-two week low of $2.80 and a fifty-two week high of $9.97.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. State Street Corp boosted its position in Humacyte by 66.1% in the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after buying an additional 1,895,529 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Humacyte by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,040,218 shares of the company’s stock valued at $11,101,000 after acquiring an additional 179,120 shares during the last quarter. Millennium Management LLC increased its stake in shares of Humacyte by 504.3% in the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after acquiring an additional 1,334,641 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Humacyte by 10.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 721,318 shares of the company’s stock worth $3,924,000 after acquiring an additional 66,946 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in shares of Humacyte by 693.0% during the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after purchasing an additional 524,600 shares during the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the sale, the director now directly owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Laura E. Niklason sold 811,172 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the sale, the chief executive officer now directly owns 2,419,712 shares in the company, valued at $10,743,521.28. This trade represents a 25.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,500,000 shares of company stock worth $6,606,799 in the last three months. Corporate insiders own 11.20% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.